Contents:

Management & Directors

Management

Eric
Dube,
PhD

President and Chief Executive Officer

Dr. Dube is the President and Chief Executive Officer of Retrophin, Inc., and serves as a member of the company's Board of Directors. He is a results-driven leader with a record of delivering innovative therapies to address significant unmet patient needs. With leadership experience across the United States, Europe and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical, and business development functions. He leads with a commitment to patients, integrating their perspective into all aspects of the company's operations.

Prior to joining Retrophin, Dr. Dube was President and Head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company's North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube's tenure at GSK, he also led the U.S. Oncology and Global Respiratory businesses.

Dr. Dube has previously been named a Fortune magazine "40 Under 40: Ones to Watch" and one of the "Emerging Pharma Leaders" by Pharmaceutical Executive. He has also been named by the Financial Times as one of the "OUTstanding 100 LGBT+ Executives."

Dr. Dube graduated from Santa Clara University with a B.S. in Biopsychology and earned an M.A. and Ph.D. in Psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community. He also completed the Finance for Senior Executives program at Harvard Business School and studied four languages.

Neil
McFarlane

Chief Operating Officer

Mr. McFarlane has served as Chief Operating Officer of Retrophin, Inc. since August 2016. Mr. McFarlane is responsible for the Company's daily operations with principal responsibility for several key functions, including commercial operations, business development, patient services, and program management. Prior to joining Retrophin, Mr. McFarlane held leadership roles at leading biopharmaceutical companies, including UCB Inc., Genzyme Inc., and Sangstat Medical Corporation. Most recently, Mr. McFarlane served as Vice President of UCB, where he was responsible for the Global Bone Business in collaboration with Amgen. Mr. McFarlane also served as Vice President and General Manager of the U.S. Immunology Business during his tenure at UCB. This was preceded by positions of increasing responsibility while at Genzyme and Sangstat. Mr. McFarlane served as an officer and enlisted soldier in the United States Army Reserves. Mr. McFarlane received his B.S. and M.S. in Nursing from the University of Florida.

Laura
M.
Clague,
CPA

Chief Financial Officer

Ms. Clague has served as Chief Financial Officer of Retrophin, Inc. since November 2014. Ms. Clague has 30 years of experience as a financial executive, and oversees the Company’s Accounting, Finance, IT and Facilities functions. Previously, Ms. Clague served as Chief Financial Officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the Vice President, Corporate Controller and Principal Accounting Officer of Amylin for 10 years, when she also served as the Chief Financial Officer of Amylin's collaboration with Eli Lilly and Company. Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation and KPMG. Ms. Clague currently serves on the board of directors of LRAD Corporation. Ms. Clague is a Certified Public Accountant in the State of California, and received a B.S. in Business Administration from Menlo College.

Noah
L.
Rosenberg,
MD

Chief Medical Officer

Dr. Rosenberg has served as Chief Medical Officer of Retrophin since July 2018 and is responsible for overseeing the Company's clinical development, as well as clinical operations, pharmacokinetics, medical affairs, patient advocacy and pharmacovigilance. He brings more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization. Previously, Dr. Rosenberg served as chief medical officer at Medimetriks Pharmaceuticals where he was responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He also served as chief medical officer of Esperion Therapeutics, where he led the design, protocol implementation, execution and monitoring of innovative clinical programs. Prior to joining Esperion, Dr. Rosenberg served as the executive director and head of cardiovascular and metabolism clinical development for the Forest Research Institute, where he led the advancement of multiple late-stage clinical trials. Earlier in his career, he held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer. Dr. Rosenberg completed his internal medicine residency at The Icahn School of Medicine at Mount Sinai Hospital and holds an M.D. from the Drexel University College of Medicine and a B.A. from Johns Hopkins University.

William "Bill"
Rote,
PhD

SVP, Research and Development

Dr. Rote has served as Senior Vice President of Research & Development (R&D) for Retrophin, Inc. since February 2017. He is responsible for discovery and translational research, regulatory affairs, quality assurance, biometrics, and technical operations including chemistry, manufacturing and controls (CMC). Prior to joining Retrophin, Dr. Rote led clinical development at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca. In this role, he was responsible for leading all aspects of clinical trial execution and analysis, including clinical operations, data management, and biostatistics. Prior to his role at Ardea, Dr. Rote held numerous positions of increasing responsibility at Amylin, including vice president and site head for R&D. He earned both his Ph.D. in Pharmacology and B.S. in Pre-Medicine from Pennsylvania State University, and received postdoctoral training from the University of Michigan.

Elizabeth
Reed

General Counsel and Corporate Secretary

Ms. Reed has served as Senior Vice President, General Counsel and Corporate Secretary of Retrophin, Inc. since January 2017. She is responsible for overseeing the Company's general legal, intellectual property, government affairs and corporate compliance functions. Previously, Ms. Reed served as General Counsel of Celladon Corporation, and prior to Celladon, served as General Counsel of Anadys Pharmaceuticals, Inc. until Anadys' acquisition by Roche. Prior to joining Anadys, she was an attorney with the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California, and received her J.D. from Harvard Law School and her B.S. in Business Administration from the University of California at Berkeley.

Directors

Gary
A.
Lyons, Chairman

Mr. Lyons has been a member of the Board of Directors of Retrophin, Inc. since 2014 and assumed the role of Chairman in May of 2016. Previously, Mr. Lyons was the founding President and Chief Executive Officer of Neurocrine Biosciences from 1993 to 2008 and remains as a member of the Board of Directors. Prior to his work at Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves as Chairman of the Board of Directors for Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. He also serves as a Director for Vical Incorporated, a biotechnology company focused on the prevention and treatment of serious or life-threatening diseases. Mr. Lyons was previously a director of PDL BioPharma, Inc., NeurogesX, Inc., and Facet Biotech Corporation. Mr. Lyons holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management

Stephen
Aselage

Mr. Aselage has been a member of the Board of Directors of Retrophin, Inc. since 2012. During his tenure as CEO of Retrophin from 2014 to January 2019, Mr. Aselage drew upon more than 30 years of biopharmaceutical experience to lead the transformation of the Company. Following his appointment, Mr. Aselage solidified the Company's leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders.

Prior to his appointment , Mr. Aselage was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the Board of Directors for Acer Therapeutics and Patara Pharma. Mr. Aselage received his B.S. in Biology from the University of Notre Dame, currently serves on the Advisory Council for the Department of Science at Notre Dame.

Roy
D.
Baynes, MD, PHD

Dr. Baynes has been a member of the Board of Directors of Retrophin, Inc. since 2016. Currently, Dr. Baynes is senior vice president of Global Clinical Development at Merck Research Laboratories. Prior to his role at Merck, Dr. Baynes was senior vice president of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of Global Clinical Development and therapeutic area head for Hematology/Oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.

Tim
Coughlin, CPA

Mr. Coughlin has been a member of the Board of Directors of Retrophin, Inc. since 2015. Tim is currently a Vice President at Neurocrine Biosciences having served as their Chief Financial Officer from September 2006 to February 2017. Mr. Coughlin has developed expertise in corporate accounting, finance, and operations management of companies ranging in size from start-ups through Fortune 500. Prior to Neurocrine, he served as Vice President of Financial Services at CHI, a nationwide integrated healthcare delivery system. From 1989 to 1999, Mr. Coughlin served as a Senior Manager in the Health Sciences practice of Ernst & Young, and its predecessors. Mr. Coughlin currently serves on the Board of Directors of Fate Therapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. Mr. Coughlin holds a Bachelor's in Accounting from Temple University and a Master's in International Business from San Diego State University.

Eric
Dube, PHD

Dr. Dube has been the President and Chief Executive Officer of Retrophin, Inc. and member of the company's Board of Directors since January 2019. He is a results-driven leader with a record of delivering innovative therapies to address significant unmet patient needs. With leadership experience across the United States, Europe and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical, and business development functions. He leads with a commitment to patients, integrating their perspective into all aspects of the company's operations. Prior to joining Retrophin, Dr. Dube was President and Head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company's North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube's tenure at GSK, he also led the U.S. Oncology and Global Respiratory businesses. Dr. Dube has previously been named a Fortune magazine "40 Under 40: Ones to Watch" and one of the "Emerging Pharma Leaders" by Pharmaceutical Executive. He has also been named by the Financial Times as one of the "OUTstanding 100 LGBT+ Executives." Dr. Dube graduated from Santa Clara University with a B.S. in Biopsychology and earned an M.A. and Ph.D. in Psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community. He also completed the Finance for Senior Executives program at Harvard Business School and studied four languages.

John
W.
Kozarich, PHD

Dr. Kozarich has been a member of the Board of Directors of Retrophin, Inc. since 2015. Dr. Kozarich has more than 35 years of experience in academia and the biopharmaceutical industry. He currently serves as Chairman of Ligand Pharmaceuticals, and Chairman and President of ActivX Biosciences. Prior to his role at ActivX, Dr. Kozarich was Vice President at Merck Research Laboratories where he was responsible for programs including antimicrobial drug discovery, enzymology, 5a-reductase biology, lipid biochemistry, nuclear receptors, ion channels and structural biology. Dr. Kozarich previously held professorships at the University of Maryland and Yale School of Medicine and currently serves as an adjunct professor of chemical physiology at the Scripps Research Institute. He was named Director of the Year for 2014 by the Corporate Directors Forum, has been honored as an American Cancer Society Faculty Research Awardee, and received the Distinguished Scientist Award of the San Diego Section of the American Chemical Society. Dr. Kozarich holds a Bachelor's of Science in chemistry from Boston College and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology and was an NIH Postdoctoral Fellow at Harvard University.

Jeffrey
A.
Meckler

Mr. Meckler has been a member of the Board of Directors of Retrophin, Inc. since 2014. He brings extensive biopharmaceutical industry experience to Retrophin and is currently the Chief Executive Officer at Intec Pharma, Ltd. – a clinical stage biopharmaceutical company focused on developing a proprietary drug delivery solution for key unmet needs. Previously, he served as CEO and a Director of Cocrystal Pharma, Inc. a pharmaceutical company focused on the discovery of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Earlier in his career, Mr. Meckler was Managing Director of the Andra Group, a life sciences consulting firm and acted as a Director and Interim CEO of Cypress Bioscience Inc. after its acquisition by Royalty Pharma. He has also served as a Director of QLT, Inc., ClearFarma USA, Kyalin Bioscience and Alveolus Inc. Mr. Meckler held a series of positions at Pfizer Inc. in Manufacturing Systems, Market Research, Business Development, Strategic Planning and Corporate Finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in Industrial Management and M.S. in Industrial Administration from Carnegie Mellon University's Tepper School of Business. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.

John
A.
Orwin

Mr. Orwin has been a member of the Board of Directors of Retrophin, Inc. since 2017. Mr. Orwin has cultivated more than 25 years of biopharmaceutical experience during tenures at some of the industry's leading companies. Currently, Mr. Orwin serves as the president and chief executive officer (CEO) of Atreca, Inc., a biopharmaceutical company focused on developing novel therapeutics based on a deep understanding of the human immune response. Prior to Atreca, Mr. Orwin also served as CEO of Relypsa, and as a director and CEO of Affymax, which was preceded by a tenure as the company's chief operating officer. In building successful businesses and commercializing a range of blockbuster products, Mr. Orwin has held leadership roles in marketing, sales, and operations for Genentech, Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin is currently a member of the board of directors of Array BioPharma Inc. and Seattle Genetics, Inc. Mr. Orwin holds a master's degree in business administration from New York University and a bachelor's degree from Rutgers, The State University of New Jersey.

Ron
Squarer

Mr. Squarer has been a member of the Board of Directors of Retrophin, Inc. since 2017. Mr. Squarer has extensive commercial, development and executive leadership expertise from a career that spans more than two decades in the biopharmaceutical industry. Since April 2012, Mr. Squarer has served as the Chief Executive Officer and a member of the Board of Directors Array BioPharma, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule therapies. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as Senior Vice President, Chief Commercial Officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor's degree in biochemistry from the University of California, Berkeley.